Cheaper drugs don't help if you never knew you had cancer
India stands at the edge of a cancer crisis that no single policy can contain. By 2045, the Indian Cancer Society projects annual diagnoses could rise from 1.5 million to 2.5 million — a surge that reflects not merely a medical challenge but a systemic failure to catch illness before it deepens. While the Union Budget's customs duty exemptions on cancer medicines offer modest relief, experts remind us that cheaper treatments matter far less when patients arrive already at the threshold of what medicine can do. The harder work — building screening infrastructure, closing regional gaps, and sustaining long-term investment — remains the unfinished obligation of a nation racing against its own demographic tide.
- India's cancer caseload could grow by nearly 67 percent within two decades, placing enormous strain on a health system already stretched thin.
- A critical flaw runs through the current reality: most patients reach hospitals only after their cancer has advanced, narrowing treatment options and dimming survival odds.
- The government's budget relief on drug import duties is a genuine but insufficient step — experts warn it addresses cost at the end of the journey, not the failures that occur at the beginning.
- Oncologists and public health voices are calling for age-appropriate screening programs and better diagnostic tools, arguing that early detection simultaneously saves lives and reduces treatment costs.
- Deep structural obstacles — regional inequality, fragmented cancer data, and weak coordination between central and state governments — continue to delay both diagnosis and care for millions.
- Civil society organizations are filling gaps with survivor-led support networks, rehabilitation centers, and digital tools, but these efforts underscore how much systemic investment is still missing.
India is moving toward a cancer crisis of significant scale. The Indian Cancer Society, marking World Cancer Day on February 4, projected that annual new cases could climb from today's 1.5 million to 2.5 million by 2045 — and paired that number with an uncomfortable warning: the path forward cannot be paved with drug price relief alone.
The Union Budget for 2026–27 did bring some good news, including customs duty exemptions on select cancer medicines and a renewed push for domestic biopharmaceutical manufacturing. Experts acknowledged the value of lower drug costs, but were careful not to overstate it. The society's Delhi chapter chair, Jyotsna Govil, drew the essential distinction: affordability at the treatment stage matters far less when patients are already presenting with advanced disease, where options are few and outcomes are poor.
The real bottleneck, as oncologist Dr. Nitesh Rohatgi made clear, is the absence of robust early detection. Timely screening does not just improve survival — it reduces what treatment ultimately costs. These programs are not supplementary; they are the foundation on which better outcomes are built. Dr. Urvashi Prasad, a cancer survivor and former NITI Aayog director, added the structural dimension: regional inequalities, weak data systems, and financial barriers continue to delay care, and only sustained coordination between the central government and states can begin to address them.
The human weight of this crisis was given voice by Renuka Prasad, secretary of the society's Delhi chapter and a cancer survivor herself. She spoke to the emotional and financial toll that extends far beyond the price of any single medicine — a toll that the society's own screening programs, rehabilitation center, and digital support tools are working, imperfectly, to ease.
The arithmetic is unsparing. Without deeper investment in screening infrastructure, regional capacity, and long-term public commitment, India will face a burden that no budget announcement, however well-intentioned, is equipped to carry.
India is heading toward a cancer crisis. By 2045, the country could be diagnosing around 2.5 million new cases annually—a jump of roughly one million from today's 1.5 million. That projection landed this week from the Indian Cancer Society, timed to World Cancer Day on February 4, and it arrived alongside a harder truth: cheaper drugs alone will not solve what's coming.
The Union Budget for 2026–27 did offer some relief. The government announced customs duty exemptions on selected cancer medicines and signaled renewed commitment to strengthening domestic biopharmaceutical manufacturing. On the surface, that looks like progress. Lower drug prices matter. But experts gathered by the Indian Cancer Society were careful not to mistake a single policy win for a solution to the larger problem. Jyotsna Govil, who chairs the society's Delhi chapter, put it plainly: the budget opens doors to more affordable treatment, but the real work is keeping patients from reaching the advanced stages where those medicines become their only hope.
That distinction matters because it points to the actual bottleneck. A substantial portion of Indians with cancer arrive at hospitals already sick—disease already advanced, treatment options already narrowed, survival odds already diminished. Dr. Nitesh Rohatgi, senior director of oncology at Fortis Memorial Hospital, presented data showing what timely screening and early detection can do: they improve survival rates and simultaneously reduce what treatment costs. Age-appropriate screening programs and better diagnostic tools are not luxuries. They are the infrastructure that transforms outcomes.
But building that infrastructure runs into obstacles that no single budget measure addresses. Dr. Urvashi Prasad, a cancer survivor and former director at NITI Aayog, named them: regional inequalities, insufficient cancer data, and financial constraints that delay diagnosis and care. She called for stronger coordination between the central government and states, and for sustained public investment in cancer care infrastructure—the kind of long-term commitment that survives budget cycles.
Renuka Prasad, secretary of the Indian Cancer Society's Delhi chapter, brought the human dimension into focus. She is a cancer survivor herself. She spoke about the emotional, physical, and financial strain the disease places on patients and their families—the weight that extends far beyond the cost of a single drug. The organization she works for runs screening programs, operates a healing and rehabilitation center called Prashanti, offers digital support through an app called Rise Against Cancer, and provides patient support services. These are not peripheral efforts. They are attempts to catch cancer earlier and to hold people up while they fight it.
The math is stark. If current trends hold, India will face nearly 67 percent more cancer diagnoses within two decades. The budget's drug exemptions help. But they are a response to a problem that should have been prevented or caught much earlier. The real work—the screening, the data systems, the regional coordination, the sustained investment—is still ahead. And it will require more than one budget announcement to accomplish.
Citações Notáveis
The budget opens the door for more affordable treatment, but our effort is to ensure patients do not reach advanced stages where these medicines become their only option.— Jyotsna Govil, Chairperson, Indian Cancer Society Delhi
Regional inequalities, insufficient cancer data, and financial constraints are key obstacles delaying diagnosis and care, requiring stronger coordination between Centre and states.— Dr. Urvashi Prasad, cancer survivor and former Director at NITI Aayog
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that cases are projected to double rather than, say, increase by 30 percent?
Because the absolute numbers become unmanageable. We're talking about an additional million people a year seeking cancer care in a system that's already strained. That's not a gradual problem you can absorb. It's a crisis that forces choices.
The budget cut customs duties on cancer drugs. Isn't that a direct response to the problem?
It's a response to one symptom. It makes treatment cheaper for people who can already access it. But most Indians with cancer don't reach treatment because they never get diagnosed early. They show up at hospitals when the disease is already advanced. A cheaper drug doesn't help if you never knew you had cancer in the first place.
So the real issue is screening and detection, not drug costs?
Both matter, but screening comes first. You can't treat what you don't know about. And early detection changes everything—survival rates improve, treatment is less intensive, costs are lower. But screening requires infrastructure, trained people, and systems that reach rural areas. That's harder to fund than a customs duty exemption.
What does regional inequality have to do with cancer?
Cancer care is concentrated in cities. If you live in a rural area or a state with weak health infrastructure, you might not have access to screening, to oncologists, to advanced diagnostics. So the same disease kills people in one region who might survive in another. That's not inevitable. It's a failure of coordination and investment.
The Indian Cancer Society runs screening programs and support services. Why isn't that enough?
Because one nonprofit, no matter how committed, cannot screen millions of people or build the infrastructure a nation needs. These organizations fill gaps, but they shouldn't have to. That's what government systems are for. The real solution requires the state to commit resources and coordination over decades, not just one budget cycle.
What happens if nothing changes?
You get what you're already seeing in advanced cases—people arriving too late, treatment options limited, survival rates lower, families bankrupted. But at a much larger scale. The crisis isn't coming. It's already here. The projection just makes it visible.